Nanjing Medlander Revenue vs. Current Valuation
| 688273 Stock | 25.66 0.54 2.15% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 340.8 M | Current Value 383.9 M | Quarterly Volatility 15.3 M |
For Nanjing Medlander profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Nanjing Medlander to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Nanjing Medlander Medical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Nanjing Medlander's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Nanjing Medlander Medical over time as well as its relative position and ranking within its peers.
Nanjing |
Nanjing Medlander Medical Current Valuation vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Nanjing Medlander's current stock value. Our valuation model uses many indicators to compare Nanjing Medlander value to that of its competitors to determine the firm's financial worth. Nanjing Medlander Medical is rated below average in revenue category among its peers. It also is rated below average in current valuation category among its peers reporting about 4.72 of Current Valuation per Revenue. At present, Nanjing Medlander's Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all model that can be used if you cannot value Nanjing Medlander by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nanjing Medlander's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Nanjing Revenue vs. Competition
Nanjing Medlander Medical is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 11.26 Billion. Nanjing Medlander holds roughly 340.82 Million in revenue claiming about 3% of equities under Health Care industry.
Nanjing Current Valuation vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Nanjing Medlander |
| = | 340.82 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Nanjing Medlander |
| = | 1.61 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Nanjing Current Valuation vs Competition
Nanjing Medlander Medical is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 44.02 Billion. Nanjing Medlander holds roughly 1.61 Billion in current valuation claiming about 4% of equities under Health Care industry.
Nanjing Medlander Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Nanjing Medlander, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Nanjing Medlander will eventually generate negative long term returns. The profitability progress is the general direction of Nanjing Medlander's change in net profit over the period of time. It can combine multiple indicators of Nanjing Medlander, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 14.4 M | 15.1 M | |
| Interest Income | 14.9 M | 15.6 M | |
| Operating Income | 74.4 M | 93.4 M | |
| Net Income From Continuing Ops | 92.5 M | 92.6 M | |
| Income Before Tax | 101.5 M | 103 M | |
| Net Income | 89.8 M | 88.6 M |
Nanjing Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Nanjing Medlander. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Nanjing Medlander position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Nanjing Medlander's important profitability drivers and their relationship over time.
Use Nanjing Medlander in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nanjing Medlander position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nanjing Medlander will appreciate offsetting losses from the drop in the long position's value.Nanjing Medlander Pair Trading
Nanjing Medlander Medical Pair Trading Analysis
The ability to find closely correlated positions to Nanjing Medlander could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nanjing Medlander when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nanjing Medlander - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nanjing Medlander Medical to buy it.
The correlation of Nanjing Medlander is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nanjing Medlander moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nanjing Medlander Medical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nanjing Medlander can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Nanjing Medlander position
In addition to having Nanjing Medlander in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Gainers Thematic Idea Now
Latest Gainers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Gainers theme has 225 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Gainers Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Nanjing Stock
To fully project Nanjing Medlander's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Nanjing Medlander Medical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Nanjing Medlander's income statement, its balance sheet, and the statement of cash flows.